Company Overview
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Why Investors Should Care
Revenue has grown at a 73.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.14.
Recent Developments
- Dec 2025 Revenue of $622.49K (-84.1% YoY); net profit $-46.90M.
- Trailing 12 Months Year-on-year growth — revenue +2.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 73.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 73.27% |
| 1 Year: | 2.00% |
Stock Price Performance
| 1 Year: | -85.80% |
| 6 Months: | -48.62% |
| 3 Months: | -77.82% |
| 1 Month: | -26.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.36 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 73.3% over 5 years.
CONS
- Trading 97.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CODX Co-Diagnostics, Inc. PHARMA | 1.12 | -0.04 | $7.82M | 0.00% | -147.54% | - | 73.27% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 2.47K | 2.60K | 9.70K | 9.70K | 9.70K | 3.40K | 61.57K | 41.43K | 1.55M | 24.04M | 21.82M | 20.02M | 27.36M | 30.10M | 22.70M | 5.02M | 5.09M | 601.96K | 197.81K | 2.46M | 467.85K | 2.66M | 641.14K | 50.28K | 162.91K | 145.38K | 145.95K |
| Gross Profit | - | - | - | 2.16K | 2.60K | 9.70K | 9.70K | 9.70K | 2.95K | 22.77K | 21.07K | 1.07M | 18.06M | 16.00M | 16.75M | 24.85M | 26.79M | 19.42M | 4.11M | 4.33M | 99.72K | -261.29K | 2.20M | 233.35K | 2.44M | 343.74K | 28.69K | 130.80K | 119.09K | -47.81K |
| Operating Income | -390.29K | -392.35K | -564.37K | -700.95K | -1.81M | -1.28M | -1.35M | -1.66M | -1.25M | -1.37M | -1.65M | -1.08M | 14.71M | 12.04M | 10.33M | 11.79M | 13.63M | 9.82M | -4.15M | -6.54M | -9.95M | -11.99M | -8.94M | -10.26M | -7.68M | -10.23M | -8.55M | -8.06M | -7.01M | -9.21M |
| Net Income | -442.64K | -449.95K | -705.74K | -855.01K | -3.89M | -1.31M | -1.37M | -1.64M | -1.37M | -1.34M | -1.75M | -1.07M | 15.01M | 15.73M | 7.90M | 9.79M | 11.48M | 11.71M | -2.69M | -1.36M | -5.76M | -8.92M | -5.98M | -9.31M | -7.60M | -9.70M | -7.53M | -7.73M | -5.89M | -9.14M |
| Diluted EPS | 1,143,939.00 | 4,141,667.00 | - | 3,529,896.00 | 1,028,969.00 | - | - | - | - | -0.08 | -0.10 | -0.05 | 0.51 | 0.53 | 0.26 | 0.33 | 0.38 | 0.34 | -0.08 | -0.04 | -0.20 | -0.31 | -0.20 | -0.31 | -0.25 | -0.32 | -7.05 | -0.23 | -0.16 | -4.06 |
| R&D Expense | 172.11K | 172.80K | 265.69K | 184.88K | 272.21K | 297.42K | 357.89K | 330.42K | 347.31K | 312.59K | 331.03K | 400.02K | 750.25K | 921.89K | 2.22M | 4.67M | 5.89M | 3.77M | 3.89M | 5.04M | 5.01M | 5.98M | 5.79M | 5.68M | 5.61M | 4.88M | 4.87M | 4.69M | 4.48M | 5.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 7.66K | 39.91K | 214.97K | 74.55M | 97.89M | 34.22M | 6.81M | 3.92M | 622.49K |
| Cost of Revenue | - | - | - | - | - | - | 5.48M | 4.18M | 999.12K | 222.38K |
| Gross Profit | - | 7.36K | 30.52K | 102.54K | 57.96M | 86.31M | 28.74M | 2.63M | 2.92M | 400.11K |
| Operating Expenses | - | - | - | - | - | - | 40.33M | 45.33M | 43.00M | 31.68M |
| Operating Income | -1.69M | -4.56M | -6.12M | -5.89M | 41.69M | 46.06M | -11.59M | -42.71M | -40.08M | -31.28M |
| EBITDA | - | - | - | - | - | - | -10.31M | -41.48M | -38.70M | -30.18M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -18.85M | -38.11M | -37.58M | -48.51M |
| Tax Provision | - | - | - | - | - | - | -4.61M | -2.78M | 57.37K | -1.62M |
| Net Income | -1.93M | -6.96M | -6.27M | -6.20M | 42.48M | 36.66M | -14.24M | -35.33M | -37.64M | -46.90M |
| Diluted EPS | - | - | - | -0.37 | 1.52 | 1.23 | -13.50 | -36.00 | -37.22 | -35.25 |
| R&D Expense | 731.47K | 1.00M | 1.36M | 1.37M | 3.19M | 14.96M | 17.44M | 22.96M | 20.98M | 19.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.30M | 4.66M | 1.55M | 2.22M | 71.24M | 160.03M | 123.09M | 95.32M | 63.56M | 24.74M |
| Total Equity | -1.15M | -2.99M | 3.85M | -1.06M | 1.74M | 66.70M | 134.48M | 114.52M | 85.58M | 53.88M | 20.63M |
| Cash & Equivalents | 33.80K | 998.74K | 3.53M | 950.24K | 893.14K | 42.98M | 88.61M | 22.97M | 14.92M | 2.94M | 11.88M |
| Long Term Debt | - | - | - | 1.91M | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.29M | 811.80K | 2.61M | 478.07K | 4.54M | 25.56M | 8.57M | 9.31M | 9.69M | 4.11M |
| Current Liabilities | - | 3.85M | 628.26K | 2.35M | 328.07K | 4.06M | 12.60M | 3.87M | 5.75M | 7.32M | 3.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.31M | -3.21M | -4.08M | -5.53M | 28.17M | 41.08M | 6.57M | -22.08M | -29.16M | -29.14M |
| Investing Cash Flow | -12.24K | -189.31K | -380.34K | -435.25K | -5.82M | 4.10M | -58.17M | 15.39M | 17.07M | 26.27M |
| Financing Cash Flow | 2.29M | 5.94M | 1.88M | 5.90M | 19.74M | 450.40K | -14.03M | -1.36M | 103.91K | 11.81M |
| Capital Expenditure | -12.24K | -129.31K | -41.34K | -113.25K | -774.40K | -669.46K | -1.43M | -1.37M | -748.35K | -700.05K |
| Free Cash Flow | -1.32M | -3.34M | -4.12M | -5.64M | 27.39M | 40.41M | 5.14M | -23.45M | -29.90M | -29.84M |
| Share Buybacks | - | - | - | - | - | - | 14.21M | 1.36M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 96.1% | 76.5% | 47.7% | 77.7% | 88.2% | 84.0% | 38.6% | 74.5% | 64.3% |
| Operating Margin % | - | -59,567.6% | -15,328.6% | -2,741.6% | 55.9% | 47.1% | -33.9% | -626.9% | -1,023.7% | -5,025.5% |
| Net Margin % | - | -90,827.9% | -15,714.3% | -2,882.0% | 57.0% | 37.5% | -41.6% | -518.7% | -961.4% | -7,533.6% |
| ROE % | 64.4% | -180.7% | 592.3% | -356.6% | 63.7% | 27.3% | -12.4% | -41.3% | -69.9% | -227.3% |
| ROCE % | 66.2% | -113.1% | 765.9% | -312.3% | 62.1% | 31.2% | -9.7% | -47.7% | -71.3% | -147.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 10.46% | 236.00K | $223.19K |
| 2 | Jane Street Group, LLC | 3.96% | 89.24K | $84.39K |
| 3 | Vanguard Capital Management LLC | 2.58% | 58.27K | $55.11K |
| 4 | Private Advisory Group LLC | 1.75% | 39.39K | $37.25K |
| 5 | Millennium Management Llc | 1.42% | 32.00K | $30.26K |
| 6 | Susquehanna International Group, LLP | 1.38% | 31.24K | $29.54K |
| 7 | Geode Capital Management, LLC | 1.13% | 25.57K | $24.19K |
| 8 | Vanguard Fiduciary Trust Co | 0.88% | 19.78K | $18.70K |
| 9 | Virtu Financial LLC | 0.78% | 17.61K | $16.66K |
| 10 | UBS Group AG | 0.71% | 16.09K | $15.22K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CODX
Medical test results can be generated without internet in India. Co-Diagnostics launched the system. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPdVlTWGhRWmU0Q1NrM2RmdmxGemNfNlJEazNZOVVjekhmbGpicUpycjdEUV9DaVBqZnRlT0xwRVhuRmd2OUVlR0FUVk9COVJ3eG5QNWw0bVJoVFhNWFo4aTFKUXREdFF5dU5DNElvQzk0Y2F0aUdZRHVzOGUwMEZhVTRaTWZ4MjluVXlTdF…
Co-Diagnostics (CODX) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQQXhYckdnNlFmT19BQlVyaUN0eDZkU01UX200N0gwTWFsUmFDR2xzMUtsWTc0VnoxRWVJczNXNnRxellNSTBBNEUyOGdGbTRFeVZXUE96Y09wMW5zZDlpd3NEZGFLbU1VdHAwRU9EMVFXbFoxWlpQcnBEbjJhclNjenJWLXVFZ01yWEhrZj…
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQdDl3Qk9BcENQaUJteUJZU285Qkd2VG00cW9Pc3NoWXBXZktzU0F2anhqSWxYcF9mSklLLXg4dWxYX3Fkd20zTmxaQzNBYnM4ZkdIQXJwQ3UwdEJKdGRDQzYtWTlSLTVHMkExWFNvQU9JbF9IMEpTT3JUNkhRMFdtdk5xV3pEd0M5ZWxHUE…
Is Co-Diagnostics National Security’s Next Diagnostic Pick? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWmMyWEEySUJ3ODF4OW50Wk1FZzctVVFhOXVQbzdwS0xfcVhfU05BUi1CaUcwVEV1RXlUNGlCLTNlaDFlR0J1VkdjNnJxUV9WUzlqRXR0emVZcVZncEplV3FzY3FmMF9rajVnNE9FQzNsTG5rallybHpPNGliOUJIb21yb0g0cUV3clp6Rn…
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNTGw2UkRJNlhjWkN2bFZVZkFFZHpYMWVibUJuN3F2Q3pvTGdTVGVUS2dkYzlnV1p1NUJXN0hkN0dBdjFYcU5hTWY2S2l4VnZrRFNkU2tKNHBTVUxNRWJ3VHVRZXl2SkZ2bzZFM3dpS211R0dvem5OYng3ZV9Ua2RSUld5V3JXSDd2VzYyM3…
CODX Looks 32.6% Undervalued on GF Value™ Amid Challenging Funda - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcmJjekpneWxIOGRYVFNiMVBZTzJ5MjJvcndVeUNEcHd2RGhPSk1yRlJicEhyM0ZBd3RvbGxhekFUT285dmlvaVVGemV1bkxZWW1fbFVDRFdFSzZDZVE5YUNxSEdlQmJhZGhqMkZGRnlZNHNuR3JNc0xnWmJZSGhWRmJ3a1k2SnRicUZ5TE…
CODX — Frequently Asked Questions
What is the current share price of Co-Diagnostics, Inc. (CODX)?
As of 2026-09-19 21:16 PDT, Co-Diagnostics, Inc. (CODX) trades at $1.12 on NasdaqCM. Its 52-week range is $1.10 to $37.80.
What is the market capitalisation of CODX?
Co-Diagnostics, Inc. (CODX) has a market capitalisation of $7.82M on NasdaqCM.
What is the P/E ratio of CODX?
CODX trades at a trailing price-to-earnings (P/E) ratio of -0.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.43.
Is CODX a good stock to buy?
This page provides a data-driven analysis of Co-Diagnostics, Inc. (CODX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.